Evidence map›Paper›PMID 23704352›Full record

ArticleJournal of cell science2013

Gain of function in the immune system caused by a ryanodine receptor 1 mutation.

Mirko Vukcevic, Francesco Zorzato, Simone Keck, Dimitrios A Tsakiris, Jennifer Keiser, Rick M Maizels, Susan Treves

Open access · greenAbstract read
In one paragraph

Article in Journal of cell science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Frontiers in immunology · 2026
    Article
  2. RyR1-mediated CaProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Article
  4. Gene×environment interactions in autism spectrum disorders.Current topics in developmental biology · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Mirko VukcevicDepartments of Anaesthesia and Biomedicine, Basel University Hospital, Hebelstrasse 20, 4031 Basel, Switzerland.
Francesco Zorzato
Simone Keck
Dimitrios A Tsakiris
Jennifer Keiser
Rick M Maizels
Susan Treves
University Hospital of Basel · CHSwiss Tropical and Public Health Institute · CHUniversity of Basel · CHUniversity of Edinburgh · GBUniversity of Ferrara · IT

Funding

Wellcome Trust 090281Wellcome Trust 095831
6 · The paper itself

Abstract

Mutations in RYR1, the gene encoding ryanodine receptor 1, are linked to a variety of neuromuscular disorders including malignant hyperthermia (MH), a pharmacogenetic hypermetabolic disease caused by dysregulation of Ca(2+) in skeletal muscle. RYR1 encodes a Ca(2+) channel that is predominantly expressed in skeletal muscle sarcoplasmic reticulum, where it is involved in releasing the Ca(2+) necessary for muscle contraction. Other tissues, however, including cells of the immune system, have been shown to express ryanodine receptor 1; in dendritic cells its activation leads to increased surface expression of major histocompatibility complex II molecules and provides synergistic signals leading to cell maturation. In the present study, we investigated the impact of an MH mutation on the immune system by studying the RYR1Y522S knock-in mouse. Our results show that there are subtle but significant differences both in resting 'non-challenged' mice as well as in mice treated with antigenic stimuli, in particular the knock-in mice: (i) have dendritic cells that are more efficient at stimulating T cell proliferation, (ii) have higher levels of natural IgG1 and IgE antibodies, and (iii) are faster and more efficient at mounting a specific immune response in the early phases of immunization. We suggest that some gain-of-function MH-linked RYR1 mutations might offer selective immune advantages to their carriers. Furthermore, our results raise the intriguing possibility that pharmacological activation of RyR1 might be exploited for the development of new classes of vaccines and adjuvants.

Indexed as

MutationAnimalsDendritic CellsDisease Models, AnimalImmunoglobulinsMaleMiceMice, Inbred C57BLMice, TransgenicNematospiroides dubiusRyanodine Receptor Calcium Release ChannelStrongylida InfectionsImmunoglobulinsRyanodine Receptor Calcium Release ChannelDendritic cellImmune systemRyanodine receptorRyR1

Identifiers

PMID23704352
PMCPMC3730249
OpenAlexW2122119730

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.